Mexican Govt Abandons Drug Tax

18 June 1995

Following unprecedented opposition in the Senate and Chamber of Deputies, Mexico's Treasury Ministry has now abandoned plans to impose 15% value added tax on medicines and food from September 1.

The strong stand taken by legislators represents a significant reversal over past actions, in which they have uniformly rubber-stamped all legislative proposals presented by the president, ministers and government agencies, according to the Marketletter's local correspondent.

Regional and national pharmacist groups had warned that imposition of the tax would cause 10,000 pharmacies to close, putting 45,000 people out of work. However, other pharmacy owners questioned in Cuernavaca and Mexico City felt that the tax would have made little difference to the slump in their business, noting that their sales have declined 30%-50% on average since the beginning of the year, and one business reporting a total drop of 70%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight